AGTC Genomics Invites Researchers to Collaborate Under MOSTI PEMACU 2.0 — Strengthening the Path from Research to Commercialization
- Feb 14
- 2 min read
Updated: Feb 15
Kuala Lumpur, Malaysia – In conjunction with the launch of the NEW MOSTI PEMACU 2.0 Grant (11 February – 31 March), AGTC Genomics is inviting universities, research centres, and innovation teams to collaborate in translating high-impact research into commercially viable outcomes.
While grant funding plays a critical role in accelerating innovation, long-term impact depends on successful validation, regulatory alignment, market positioning, and industry deployment. AGTC Genomics positions itself not merely as a service provider, but as a structured industry R&D partner capable of supporting projects beyond the grant lifecycle.
A Proven Malaysian DeepTech Platform
AGTC Genomics is a Malaysian BioNexus-status deeptech company operating an advanced genomics laboratory with established sequencing platforms, bioinformatics pipelines, and clinical-grade workflows. The company has built a track record in translating genomic technologies into deployable clinical and industrial applications.
“Our focus has always been translational impact,” said a spokesperson from AGTC Genomics. “Innovation must move beyond proof-of-concept. It must be validated, structured for regulatory compliance, and positioned for sustainable adoption.”
Track Record in Commercialization and Deployment
AGTC Genomics has successfully:
Developed and launched proprietary genomic diagnostic panels
Implemented clinical NGS workflows within hospital ecosystems
Navigated accreditation and regulatory frameworks
Structured industry–university collaborations with defined IP pathways
Built operational models that generate sustainable revenue streams
This experience enables research teams to design PEMACU 2.0 proposals with commercialization embedded from the outset, rather than as a secondary consideration.
Strengthening Research Proposals with Industrial Readiness
Under the PEMACU 2.0 framework, AGTC Genomics supports research teams in:
Refining experimental design with translational endpoints
Structuring milestone-driven development plans
Mapping regulatory and compliance pathways
Developing commercialization and deployment strategies
Planning scalability and industry integration
The company also emphasizes transparent intellectual property management, ensuring clarity in ownership and fair collaboration models between institutions and industry partners.
Expert-Guided Strategic Support
Through its network of national and international experts across clinical, regulatory, scientific, and commercialization domains, AGTC Genomics provides structured guidance to ensure projects are technically sound and strategically positioned for market translation.
Invitation for Institutional Engagement
AGTC Genomics welcomes group or institution-wide discussions with research centres preparing PEMACU 2.0 applications. Its scientific team is available to engage in structured brainstorming sessions and roadmap planning to align research objectives with deliverable, measurable, and commercially relevant outcomes.
For collaboration discussions under the MOSTI PEMACU 2.0 Grant, institutions may contact AGTC Genomics to explore partnership opportunities.
About AGTC Genomics
AGTC Genomics is a Malaysian BioNexus-status deeptech company specializing in advanced genomics and molecular diagnostics. The company focuses on translating research innovation into validated, scalable, and commercially sustainable precision medicine solutions, supported by structured R&D pipelines and industry-grade operational frameworks.
Comments